TNB Tech Minute: Microsoft Expands Partnership With Mistral AI

Summary

---

WSJ Tech News Briefing: Microsoft Expands Partnership With Mistral AI

Date: July 21, 2026
Host: Imani Moiz
Episode Theme:
A succinct briefing on Microsoft's major AI partnership moves in Europe, the intensifying battle among global AI players, and pharmaceutical litigation over weight-loss drug advertising.

---

Main Theme / Purpose

This episode explores Microsoft's deepening investment in the French AI startup Mistral AI, strategic implications for European cloud and AI markets, ripple effects from new Chinese AI models on American tech valuations, and a legal showdown between major pharmaceutical companies over weight-loss drug advertising.

---

Key Discussion Points & Insights

---

1. Microsoft & Mistral AI: Expanding European AI Infrastructure

[00:14 – 01:12]

• Deal Details:

  • Microsoft is committing multiple billions of dollars to help France’s Mistral AI build data centers in Europe.
  • Two of Mistral's leading AI models will become available in Microsoft products.

• Strategic Motive:

  • Both firms aim to expand their presence with European enterprise AI clients, positioning themselves against strong competition from U.S. and European tech giants.

• Financial Dynamics:

  • Financial specifics are undisclosed.
  • A Microsoft executive describes a two-way return:
    • "Microsoft expects to get a return when customers use its cloud platform, while Mistral will get a return when customers use its AI models."

Notable Quote

"Microsoft is expanding its AI partnership with Mistral AI, making a multibillion-dollar commitment to help the French startup build data centers in Europe."
— Imani Moiz, [00:20]

---

2. Novo Nordisk Lawsuit Against Eli Lilly Over Drug Advertising

[01:13 – 01:48]

• Background:

  • Novo Nordisk, maker of Ozempic and Wegovy, has sued Eli Lilly for alleged deceptive advertising.
  • Claims focus on Eli Lilly's use of outdated studies to market its weight-loss drugs (Manjaro and Zepbound) as more effective.

• Novo Nordisk's Position:

  • More recent data, according to the company, indicates their drugs offer comparable weight loss.

• Legal & PR Steps:

  • Novo Nordisk issued a cease and desist letter in April; says Eli Lilly did not respond.
  • Eli Lilly did not comment for this report.

Notable Quote

"Novo Nordisk sent a cease and desist letter to Eli Lilly in April demanding that the company suspend the advertising, but said it didn't receive a response."
— Imani Moiz, [01:38]

---

3. Rising Chinese AI Challengers & Impact on US AI Valuations

[01:49 – 02:10]

• Key Development:

  • Moonshot AI, a leading Chinese lab, released the open-weight Kimi K3 model—hailed as competitive with America’s best closed-source systems.

• Market Impact:

  • This launch is “fueling doubts about the long term business models of OpenAI and Anthropic.”
  • Since the Kimi K3 release, $392 billion has been wiped off the anticipated valuations of OpenAI and Anthropic.

• IPO Implications:

  • Both American companies still plan to go public later this year, but face new skepticism.

Notable Quote

“A collective $392 billion has been wiped off their expected valuations since Kimi's release last Friday.”
— Imani Moiz, [02:05]

---

Memorable Moments & Quotes

• Multi-Billion Dollar AI Deal:

  “Microsoft is expanding its AI partnership with Mistral AI, making a multi billion dollar commitment to help the French startup build data centers in Europe.”
  — Imani Moiz, [00:20]

• Pharma Showdown:

  “Novo Nordisk sent a cease and desist letter to Eli Lilly in April demanding that the company suspend the advertising, but said it didn't receive a response.”
  — Imani Moiz, [01:38]

• China’s AI Disruption:

  “Moonshot AI's openweight Kimi K3 model…is fueling doubts about the long term business models of OpenAI and Anthropic.”
  — Imani Moiz, [01:53]

• Valuation Shockwave:

  “A collective $392 billion has been wiped off their expected valuations since Kimi's release last Friday.”
  — Imani Moiz, [02:05]

---

(Related Content) The Human Side of AI Transformation

[02:24 – 02:54]
Short insight from Dan Swan, McKinsey, in a sponsored segment:

• Human skills and organizational models need rewiring alongside the rollout of new AI tools.
• Example: Analytical skills are now less in demand than the ability to prompt AI effectively.
• Changing company operating models and people’s capabilities is the key to unlocking AI’s true value.

Notable Quote

“Whereas before you may need to be really good at analysis, now the skill might be how do you prompt these tools to get the right answers and outcomes…when you see that all humming together, it can be really, really special.”
— Dan Swan, [02:27]

---

Important Timestamps

• [00:14] – Microsoft and Mistral AI partnership details
• [01:13] – Novo Nordisk sues Eli Lilly for deceptive advertising
• [01:49] – Chinese AI gains challenge U.S. market dominance, impact on OpenAI and Anthropic
• [02:24] – (Sponsored) McKinsey on human skills and AI transformation

---

Summary

This Tech Minute covers the fierce battle for AI dominance in Europe and beyond, with Microsoft and Mistral AI forging a high-stakes alliance as Chinese AI breakthroughs threaten U.S. leaders’ future business models and market caps. Meanwhile, pharma giants Novo Nordisk and Eli Lilly are locked in a legal dispute over how weight-loss drugs are marketed to the public. The episode punctuates the need for business and human adaptation in the fast-changing AI landscape.

Transcript

[A]

Countless companies invest in AI tools without tying them to tangible business outcomes. Join McKinsey later to learn how leaders rewire their organizations for sustained impact and value.

[B]

Here's your morning TNB Tech minute for Tuesday, July 21st. I'm Imani Moiz for the Wall Street Journal. Microsoft is expanding its AI partnership with Mistral AI, making a multi billion dollar commitment to help the French startup build data centers in Europe. The deal is the latest attempt by both companies to reach more European enterprise AI clients as they face fierce competition from rival AI Labs and other US Tech giants. As part of the deal, two of Mistral's top AI models will be available in Microsoft's products. The companies declined to specify the financial terms of the deal, but a Microsoft executive said the tech giant expects to get a return when customers use its cloud platform, while Mistral will get a return when customers use its AI models. Ozempic maker Novo Nordisk has filed a lawsuit against Eli Lilly, arguing it uses deceptive advertising to mislead customers. The complaint accuses Eli Lilly of using outdated studies to promote its branded GLP1 drugs Manjaro and Zepbound, as helping customers lose significantly more weight on average than Ozempic and Wegovy, which is owned by Novo Nordisk. And the company says that in reality, more recent data shows that its drugs can help patients lose a comparable amount of weight. Novo Nordisk sent a cease and desist letter to Eli Lilly in April demanding that the company suspend the advertising, but said it didn't receive a response. Eli Lilly didn't immediately respond to a request for comment. And the latest AI model launches out of China are rattling expectations for the biggest AI players in the U.S. analysts say. Moonshot AI's openweight Kimi K3 model, which is said to already be competitive with America's best closed systems, is fueling doubts about the long term business models of OpenAI and anthropic. Both American companies are expected to go public later this year. A collective $392 billion has been wiped off their expected valuations since Kimi's release last Friday. And that's your TNB Tech Minute. We'll be back this afternoon with more

[A]

AI Transformation is more than a tech initiative. It requires a broader rewiring of human skills and ways of working. Here's Dan Swan, senior partner at McKinsey

[C]

one of the biggest unlocks we see is the human being capabilities around the technology. Whereas before you may need to be really good at analysis, now the skill might be how do you prompt these tools to get the right answers and outcomes. And so for us, it's a really big priority to help companies to understand how do you need to change the operating model of your organization and change the underlying capabilities of the people that are interacting with the technology. And when you see that all humming together, it can be really, really special.

[A]

Discover how McKinsey helps organizations rewire to out compete with [e-mail] TechMoves this content

[D]

was created by Custom Content from WSJ, a unit of the Wall Street Journal advertising department.